Gain Therapeutics Inc (GANX) - Net Assets
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has net assets worth $5.91 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.97 Million) and total liabilities ($5.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Gain Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.91 Million |
| % of Total Assets | 53.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | 18.34% |
| 10-Year Change | N/A |
| Growth Volatility | 217.27 |
Gain Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Gain Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Gain Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Gain Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Gain Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see GANX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.34 Million | -41.65% |
| 2023-12-31 | $12.58 Million | -33.38% |
| 2022-12-31 | $18.88 Million | -45.78% |
| 2021-12-31 | $34.82 Million | +461.39% |
| 2020-12-31 | $6.20 Million | +1478.66% |
| 2019-12-31 | $-449.86K | +52.69% |
| 2018-12-31 | $-950.91K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gain Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7993118200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.71K | 0.04% |
| Other Comprehensive Income | $-247.55K | -3.37% |
| Other Components | $88.78 Million | 1209.60% |
| Total Equity | $7.34 Million | 100.00% |
Gain Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Gain Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medicalg
WAR:MDG
|
$72.31 Million |
|
Clene Inc.
NASDAQ:CLNN
|
$72.32 Million |
|
GO Element Co. Ltd.
KQ:311320
|
$72.32 Million |
|
Woosu AMS Co.Ltd
KQ:066590
|
$72.34 Million |
|
Eaton Vance California MIT
NYSE MKT:CEV
|
$72.31 Million |
|
Humax Holdings Co. Ltd
KQ:028080
|
$72.29 Million |
|
Vortex Consolidated Bhd
KLSE:0060
|
$72.28 Million |
|
Children’s Place Inc
NASDAQ:PLCE
|
$72.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gain Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,578,224 to 7,339,574, a change of -5,238,650 (-41.6%).
- Net loss of 20,411,191 reduced equity.
- New share issuances of 13,212,311 increased equity.
- Other comprehensive income decreased equity by 494,790.
- Other factors increased equity by 2,455,020.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.41 Million | -278.1% |
| Share Issuances | $13.21 Million | +180.01% |
| Other Comprehensive Income | $-494.79K | -6.74% |
| Other Changes | $2.46 Million | +33.45% |
| Total Change | $- | -41.65% |
Book Value vs Market Value Analysis
This analysis compares Gain Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.16 | $1.88 | x |
| 2019-12-31 | $-0.05 | $1.88 | x |
| 2020-12-31 | $0.52 | $1.88 | x |
| 2021-12-31 | $3.43 | $1.88 | x |
| 2022-12-31 | $1.59 | $1.88 | x |
| 2023-12-31 | $0.97 | $1.88 | x |
| 2024-12-31 | $0.32 | $1.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gain Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -278.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.65x
- Recent ROE (-278.10%) is below the historical average (-92.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -5364.36% | 0.03x | 0.00x | $-1.01 Million |
| 2019 | 0.00% | -5310.88% | 0.06x | 0.00x | $-2.15 Million |
| 2020 | -57.69% | -12387.67% | 0.00x | 1.55x | $-4.20 Million |
| 2021 | -39.90% | -10371.70% | 0.00x | 1.12x | $-17.37 Million |
| 2022 | -93.17% | -13262.02% | 0.01x | 1.28x | $-19.48 Million |
| 2023 | -177.03% | -40354.33% | 0.00x | 1.48x | $-23.53 Million |
| 2024 | -278.10% | 0.00% | 0.00x | 1.65x | $-21.15 Million |
Industry Comparison
This section compares Gain Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gain Therapeutics Inc (GANX) | $5.91 Million | 0.00% | 0.86x | $72.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the … Read more